Visit Contract Pharma
at Booth #1921

PCI Marks 80th Serialization Installation

11.09.18

Continues strategy of significant serialization and anti-counterfeiting technology investment

PCI Pharma Services is celebrating a significant milestone in the protection of global drug products with the installation of its 80th serialization line. PCI continues to invest heavily in services advancing the commercialization of therapies destined to domestic and global markets, supporting medicines destined to more than 100 countries around the world.
 
PCI’s preparedness for global product security requirements has spanned more than seven years, with support for products meeting the U.S. Drug Supply Chain Security Act (DSCSA), EU’s Falsified Medicines Directive (FMD), as well as in-country requirements in emerging markets including South Korea, Russia, China, Brazil, Saudi Arabia, and Turkey among others. With our expert architecture, clients enjoy singular connectivity to access the entirety of PCI’s extensive global supply network in delivering serialized medicines with integrated overt and covert anti-counterfeiting protection features.
 
“It’s been a long journey,” said Brad Payne, senior vice president of global operations, PCI. “At the earliest stages of our preparedness, we leveraged our knowledge and looked to implement a strategy that focused on the industry leading experience for our customers, pairing the best technologies while maximizing ease of use, all with an eye towards allowing for scalability—knowing that at some point we would see the market finally reach maturity in terms of firm governmental requirements and a common framework. 
 
“Considerable credit needs to be given to organizations like GS1 for the work they have done in working to develop some market standards. The industry still has a ways to go in coalescing around a truly common standard, but PCI has been able to leverage an adaptable solution that allows us to meet the requirements of established markets as well as those countries which are still in flux with shifting or developing standards. The biopharmaceutical industry is truly a global business and we are helping clients meet the requirements for all markets around the world, ensuring safe and effective supplies of lifesaving medicines for all patients.”